减低剂量去甲氧柔红霉素联合阿糖胞苷方案治疗老年急性髓细胞白血病的临床研究

目的:探讨减低剂量去甲柔红霉素联合阿糖胞苷(IA)方案治疗老年急性髓细胞白血病(AML)患者的疗效。方法:收集我院老年急性髓细胞白血病患者62例,随机分成减低剂量IA治疗组和标准剂量IA对照组,两组均实施3+7治疗方案。治疗2个疗程,比较两组不良反应和临床疗效。结果:减低剂量IA治疗组总CR率和CCR率分别为75.0%和66.7%;标准剂量IA对照组总CR率和CCR率分别为50.0%和33.3%。减低剂量IA治疗组总生存期25+月较标准剂量IA对照组生存期23+月延长。结论:对于老年急性髓细胞白血病患者,减低剂量IA治疗方案的CR率和CCR率与标准剂量IA治疗方案相比具有明显疗效优势。

The Clinical Study of Dose-reduced Idarubicin and Cytarabine as Therapeutic Regimen in Elderly Patients with Acute Myeloid Leukemia

Objective:To investigate the curative effect of dose- reduced idarubicin and cytarabine (IA) as therapeutic regimen in elderly patients with acute myeloid leukemia (AML).Methods:62 cases of elderly patients with acute myeloid leukemia were collected and randomly divided into reduced dose IA therapy group and the standard dose IA control group, and both of the two groups received 3+7 treatment. The clinical efficacy and adverse reactions of the two groups were compared after two courses of treatment.Results:The total CR rate and CCR rate of reduced dose IA therapy group were 75% and 66.7%, and in standard dose IA control group, they were 50% and 33.3%, respectively. The overall survival of therapy group (25+ month) had extended when compared with that of the control group (23+ months).Conclusion:Reduced dose IA astherapeutic regimen in elderly patients with acute myeloid leukemia has obvious advantage in curative effect when compared with the standard dose IA treament.